<DOC>
	<DOCNO>NCT01121406</DOCNO>
	<brief_summary>This international , randomized phase II trial . The aim ass efficacy safety BI 6727 Versus investigator 's best choice single agent cytotoxic recurrent third fourth line platinum resistant/refractory ovarian cancer . 100 patient randomise study entry receive either BI 6727 ( Arm A : 50 patient ) non-platinum single agent cytotoxic ( Arm B : 50 patient ) Treatment continue disease progression unacceptable toxicity . Primary endpoint : disease control rate week 24 accord Response Evaluation Criteria In Solid Tumours version 1.1 . Secondary endpoint : efficacy ( progression free survival , overall survival , biological tumour response , biological progression free survival assess serum CA 125 accord Gynecologic Cancer Intergroup criterion , safety accord NCI CTCAE v.3 , disease symptom control assess EORTC QLQ-C30 , QLQ-OV28 individual symptom questionnaire , pharmacokinetics BI 6727 . Others endpoint : biomarkers pharmacogenetics analysis ( optional )</brief_summary>
	<brief_title>BI 6727 ( Volasertib ) Randomised Trial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion : 1 . Confirmed recurrent epithelial ovarian carcinoma , peritoneal carcinoma fallopian tube carcinoma . 2 . Platinum resistant platinum refractory disease . 3 . Eastern Collaborative Oncology Group performance status &lt; = 2 . 4 . Life expectancy &gt; = 3 month . 5 . At least one measurable lesion ( Response Evaluation Criteria In Solid Tumours version 1.1 ) . 6 . Adequate hepatic , renal bone marrow function . 7. sign write informed consent prior admission study . Exclusion criterion : 1 . Contreindications cytotoxic treatment accord Summary Product Characteristics ( Arm B ) . 2 . Clinical evidence active brain metastasis leptomeningeal involvement . 3 . Other malignancy currently require active therapy . 4 . QTc prolongation accord Fridericia formula deem clinically relevant investigator ( e.g. , congenital long QT syndrome , QTc accord Fridericia formula &gt; 470 m ) . 5 . Hypersensitivity one trial drug excipients . 6 . Serious illness concomitant non oncological disease . 7 . Systemic anticancer therapy within 4 week start study . 8 . Evidence ileus sor sub ileus .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>